Investigating how to measure cognitive function in patients with immune thrombotic thrombocytopenic purpura (iTTP)
A Clinical Trial Readiness Study of Patient Reported Outcome Measures in Thrombotic Thrombocytopenic Purpura (TTP)
This study is looking to better understand how immune thrombotic thrombocytopenic purpura (iTTP) affects thinking and memory, so that patients can share their experiences and help improve treatments for their cognitive challenges.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10947615 on NIH RePORTER |
What this research studies
This research focuses on improving the assessment of cognitive function in patients with immune thrombotic thrombocytopenic purpura (iTTP), a rare blood disorder. It aims to develop and validate patient-reported outcome measures that accurately reflect the cognitive challenges faced by these patients. By conducting a comprehensive evaluation of cognitive function, the study seeks to align clinical trials with FDA recommendations for patient-focused drug development. This will ultimately help ensure that new therapies can be effectively evaluated for their impact on cognitive health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with immune thrombotic thrombocytopenic purpura (iTTP) who experience cognitive function issues.
Not a fit: Patients who do not have iTTP or those whose cognitive function is not significantly affected by the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment options for patients with iTTP by ensuring that cognitive function improvements are accurately measured and reported.
How similar studies have performed: While there have been studies on cognitive function in other conditions, this specific approach to validating cognitive measures in iTTP is novel and has not been extensively tested.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Onwuemene, Oluwatoyosi Adefunke — Duke University
- Study coordinator: Onwuemene, Oluwatoyosi Adefunke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.